Literature DB >> 33211910

An Association Between the Inflammatory Biomarker GlycA and Depressive Symptom Severity.

Samara Huckvale1, Stephanie Reyes1, Alexandra Kulikova1, Anand Rohatgi2, Kayla A Riggs2, E Sherwood Brown3,1.   

Abstract

OBJECTIVE: The underlying mechanisms of depression remain unclear; however, current literature suggests a relationship between inflammation and depression. The association between the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) and depression has been previously investigated, but the relationship between GlycA, a novel spectroscopic inflammatory biomarker, and depression does not appear to have been examined.
METHODS: Data were obtained from The Dallas Heart Study (DHS, conducted between 2000 and 2002), which consisted of a large community-based sample of Dallas County residents (N = 3,033). Depressive symptom severity was assessed with the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR). It was hypothesized that the serum GlycA level would be a statistically significant predictor of QIDS-SR scores after control for demographic covariates. Multiple linear regression was used to assess the relationship between GlycA level and QIDS-SR scores. The role of hs-CRP in predicting QIDS-SR scores was also explored.
RESULTS: GlycA level was a statistically significant positive predictor of QIDS-SR score (β = .053, P = .038) with control for sex, age, antidepressant use, ethnicity, smoking status, drinking status, body mass index, and years of education. In a subset of adults with moderate-to-severe depression, GlycA level was not associated with QIDS-SR scores. Additionally, hs-CRP level was not a statistically significant predictor of QIDS-SR scores.
CONCLUSIONS: This study found a positive association between the inflammatory biomarker GlycA, but not hs-CRP, and depressive symptom severity in a large multiethnic and multiracial community-based sample. Thus, these results provide the first indication that GlycA may be a potentially useful novel biomarker of depression. © Copyright 2020 Physicians Postgraduate Press, Inc.

Entities:  

Year:  2020        PMID: 33211910      PMCID: PMC7932005          DOI: 10.4088/JCP.20m13245

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  41 in total

Review 1.  Proinflammatory cytokines.

Authors:  C A Dinarello
Journal:  Chest       Date:  2000-08       Impact factor: 9.410

Review 2.  Is depression an inflammatory disorder?

Authors:  Charles L Raison; Andrew H Miller
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

3.  The pro-inflammatory profile of depressed patients is (partly) related to obesity.

Authors:  Richard C Shelton; Michael Falola; Li Li; John Zajecka; Maurizio Fava; George I Papakostas
Journal:  J Psychiatr Res       Date:  2015-09-03       Impact factor: 4.791

4.  GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation.

Authors:  James D Otvos; Irina Shalaurova; Justyna Wolak-Dinsmore; Margery A Connelly; Rachel H Mackey; James H Stein; Russell P Tracy
Journal:  Clin Chem       Date:  2015-03-16       Impact factor: 8.327

5.  Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression.

Authors:  A M Myint; Y K Kim
Journal:  Med Hypotheses       Date:  2003 Nov-Dec       Impact factor: 1.538

Review 6.  CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.

Authors:  Vyara Valkanova; Klaus P Ebmeier; Charlotte L Allan
Journal:  J Affect Disord       Date:  2013-07-17       Impact factor: 4.839

7.  The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Authors:  A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

8.  An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

Authors:  Rudolf Uher; Katherine E Tansey; Tracy Dew; Wolfgang Maier; Ole Mors; Joanna Hauser; Mojca Zvezdana Dernovsek; Neven Henigsberg; Daniel Souery; Anne Farmer; Peter McGuffin
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

9.  Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression.

Authors:  E Haroon; C C Fleischer; J C Felger; X Chen; B J Woolwine; T Patel; X P Hu; A H Miller
Journal:  Mol Psychiatry       Date:  2016-01-12       Impact factor: 15.992

10.  Elevated GlycA in severe obesity is normalized by bariatric surgery.

Authors:  Arun Manmadhan; Bing-Xue Lin; Judy Zhong; Manish Parikh; Jeffrey S Berger; Edward A Fisher; Sean P Heffron
Journal:  Diabetes Obes Metab       Date:  2018-08-28       Impact factor: 6.577

View more
  2 in total

1.  Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample.

Authors:  Darlene R King; Damilola C Salako; Samia Kate Arthur-Bentil; Arielle E Rubin; Jay B Italiya; Jenny S Tan; Dimitri G Macris; Hunter K Neely; Jayme M Palka; Justin L Grodin; Kaylee Davis-Bordovsky; Matthew Faubion; Carol S North; E Sherwood Brown
Journal:  J Affect Disord       Date:  2020-12-15       Impact factor: 4.839

2.  Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism.

Authors:  Daniel E Radford-Smith; Preya J Patel; Katharine M Irvine; Anthony Russell; Dan Siskind; Daniel C Anthony; Elizabeth E Powell; Fay Probert
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.